Previous studies have reported that the ability of p53 to control the expression of ERα could suggest that specific p53 mutations in breast tumours may contribute not only to oncogenesis and drug resistance, but also to the more aggressive phenotype associated with the loss of ER expression. This evidence concerns the gene TP53 and breast neoplasm.